Review on Medusa^®:a polymer-based sustained release technology for protein and peptide drugs

Bibliography

• SHI Y, LI LC: Current advances in sustained-release systems for parenteral drug delivery. Expert Opin. Drug Devel. (2005) 2:1039-1058.
   PubMedGoogle Scholar
• STROM G, OUSSOREN C, PEETERS P, BARNHOLZ Y: Tolerability of liposomes in vivo. In: Liposome Technology. Gregoriadis G (Ed.), CRC Press, Boca Raton, FL, USA (1993):345-383.
   Google Scholar
• CEH B, WINTERHALTER M, FREDERIK PM, VALLNER JJ, LASCI DD: Stealth liposomes: from theory to product. Adv. Drug Del. Rev. (1997) 24:165-177.
   Web of Science ®Google Scholar
• MANTRIPRAGADA S: A lipid based Depot (DepoFoam® technology) for sustained release drug delivery. Prog. Lipid Res. (2002) 41:392-406.
   PubMed Web of Science ®Google Scholar
• REITHMEIER H, HERRMANN J, GOPFERICH A: Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int. J. Pharm. (2001) 218:133-143.
   Google Scholar
• REITHMEIER H, HERRMANN J, GOPFERICH A: Lipid microparticles as a parenteral controlled device for peptides. J. Control Release (2001) 73:339-350.
   PubMed Web of Science ®Google Scholar
• PAPAHADJOPOULOS D, VAIL WJ, JACOBSON K, POST G: Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta (1975) 394:483-491.
   PubMed Web of Science ®Google Scholar
• DELMAS G, PARK S, CHEN ZW et al.: Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob. Agents Chemother. (2002) 46:2704-2707.
   PubMed Web of Science ®Google Scholar
• BRACHO G, LASTRE M, CAMPO JD et al.: Proteoliposome derived cochleate as novel adjuvant. Vaccine (2006) 24(Suppl. 2):S2-S30-S31.
   Web of Science ®Google Scholar
• GIBSON B, DUFFY AM, GOULD FOGERITE S et al.: A novel gene delivery system for mammalian cells. Anticancer Res. (2004) 24:483-488.
   PubMed Web of Science ®Google Scholar
• PACKHAEUSER C, SCHNIEDERS J, OSTER CG, KISSEL T: In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. (2004) 58:445-455.
   PubMed Web of Science ®Google Scholar
• SARTOR O: Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology (2003) 61(2 Suppl. 1):25-31.
   PubMed Web of Science ®Google Scholar
• ZENTNER GM, RATHI R, SHIH C et al.: Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control Release (2001) 72:203-215.
   PubMed Web of Science ®Google Scholar
• MASAKI T, RATHI R, ZENTNER G et al.: Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int. (2004) 66:2061-2069.
   PubMed Web of Science ®Google Scholar
• HELLER J, BARR J: Biochronomer technology. Expert Opin. Drug Deliv. (2005) 2:169-183.
   PubMed Web of Science ®Google Scholar
• FLEMING AB, SALTZMAN WM: Pharmacokinetics of the carmustine implant. Clin. Pharmacokinet. (2002) 41:403-419.
   PubMed Web of Science ®Google Scholar
• ALLABABIDI S, SHAH JC: Efficacy and pharmacokinetics of site-specific cefrazolin delivery using biodegradable implants in the prevention of post-operative wound infections. Pharm. Res. (1998) 15:323-333.
   Google Scholar
• WRIGHT JC, TAO LEONARD ST, STEVENSON CL et al.: An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control Release (2001) 75:1-10.
   PubMed Web of Science ®Google Scholar
• CUI F, CUN D, TAO A et al.: Preparation and characterization of melittin-loaded poly (DL-lactic acid) or poly (DL-lactic-co-glycolic acid) microspheres made by the double emulsion method. J. Control Release (2005) 107:310-319.
   PubMed Web of Science ®Google Scholar
• CLELAND JL, DUENAS E, DAUGHERTY A et al.: Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect. J. Control Release (1997) 49:193-205.
   Web of Science ®Google Scholar
• CLELAND JL, JOHNSON OL, PUTNEY S et al.: Recombinant human growth hormone poly(lactic-go-glycolic acid) microsphere formulation development. Adv. Drug Deliv. Rev. (1997) 28:71-84.
   PubMed Web of Science ®Google Scholar
• MU L, FENG SS: A novel controlled release formulation for anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J. Control Release (1997) 86:33-48.
   Google Scholar
• FENG SS, MU L, WIN KY et al.: Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. (2004) 11:413-424.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, HUEY LEE S, FENG SS: Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials (2007) 28:1889-1899.
   PubMed Web of Science ®Google Scholar
• LI KW, DANG W, TYLER BM et al.: Polilactofate microparticles for paclitaxel delivery to central nervous system malignancies. Clin. Cancer Res. (2003) 9:3441-3447.
   PubMed Web of Science ®Google Scholar
• KUMAR N, LANGER RS, DOMB AJ: Polynhydrides: and overview. Adv. Drug Del. Rev. (2002) 54:889-910.
   PubMed Web of Science ®Google Scholar
• FRANSSEN O, VENDERVENNET L, RODERS P, HENNINK WE: Degradable dextran hydrogels: controlled release of a model protein from cylinders and microspheres. J. Control Release (1999) 60:211-221.
   PubMed Web of Science ®Google Scholar
• CHUNG JT, VLUGT-WENSINK KDF, HENNINK WE, ZHANG Z: Effect of polymerization conditions on the network properties of dex-HEMA microspheres and macro-hydrogels. Int. J. Pharm. (2005) 288:51-61.
   PubMed Web of Science ®Google Scholar
• CADEE JA, DE GROOT CJ, JISKOOT W, OTTER WD, HENNINK WE: Release of recombinant human interleukin-2 from dextran-based hydrogels. J. Control Release (2002) 778:1-13.
   Google Scholar
• KOTEN JW, LUYN MJ, CADEE JA et al.: IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine (2003) 24:57-66.
   PubMed Web of Science ®Google Scholar
• DE GROOT CJ, VAN LUYN MJ, VAN DIJK-WOLTHUIS WN et al.: In vivo biocompatibility of biodegradable dextran-based hydrogels tested with human fibroblasts. Biomaterials (2001) 22:1197-1203.
   PubMed Web of Science ®Google Scholar
• KIM SJ, HAHN SK, KIM MJ et al.: Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J. Control Release (2005) 104:323-335.
   PubMed Web of Science ®Google Scholar
• GOVARDHAN C, KHALAF N, JUNG CW et al.: Novel long-acting crystal formulation of human growth hormone. Pharmaceutical Res. (2005) 22:1461-1470.
   PubMed Web of Science ®Google Scholar
• OUDARD S, THIOUNN H, FRIDMAN D et al.: Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. ASCO Meeting Abstracts (2006) 24:2558.
   Google Scholar
• TREPO C, MEYRUEIX R, MAYNARD M et al.: Novel sustained release formulation of IFN α-2b improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial. J. Clin. Virol. (2006) 36:S24.
   PubMed Web of Science ®Google Scholar
• CONSTANCIS A, MEYRUEIX R, BRYSON N et al.: Macromolecular colloids of diblock poly(amino acids) that bind insulin. J. Colloid Interface Sci. (1999) 217:357-368.
   PubMed Web of Science ®Google Scholar